ZymoGenetics’ senior vice president of sales and marketing, Michael Dwyer, has left the company as of yesterday, according to a regulatory filing. The Seattle-based company (NASDAQ: [[ticker:ZGEN]]) didn’t explain why he left, or financial terms of his departure. Dwyer joined the company in April 2006 to commercialize its first FDA-approved drug, recombinant thrombin (Recothrom). The drug has gotten off to a slow start, generating an estimated $7 million in U.S. sales in 2008.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
